0000000000385549

AUTHOR

Michael G. Kiehl

showing 4 related works from this author

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

2010

The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 μg/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/μL. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 …

AdultCompassionate Use TrialsMalemedicine.medical_specialtyBenzylaminesAdolescentStem cell mobilizationmedicine.medical_treatmentCyclamsPoor mobilizersGermanYoung AdultHeterocyclic CompoundsGermanyGranulocyte Colony-Stimulating FactormedicineHumansIntensive care medicineChildAgedTransplantationChemotherapybusiness.industryPlerixaforLymphoma Non-HodgkinHematopoietic Stem Cell TransplantationCompassionate UseHematologyMiddle AgedCombined Modality TherapyHodgkin Diseasehumanitieslanguage.human_languageHematopoietic Stem Cell MobilizationTreatment OutcomeChild PreschoollanguageBlood Component RemovalFemalebusinessMultiple Myelomamedicine.drugBone marrow transplantation
researchProduct

Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients

2003

Patients with severe neutropenia lasting for more than 10 days, who develop fever and pulmonary infiltrates, are at high risk of treatment failure and infection-related death, under conventional broad-spectrum antibiotics. Early supplementation by a systemic antifungal therapy active against Aspergillus spp. has been shown to markedly improve their clinical outcome. Prognosis is significantly influenced by early identification of lung infiltrates by means of high-resolution thoracic computed tomography. Non-culture based diagnostic procedures using a highly sensitive Sandwich ELISA assay to detect circulating galactomannan, or PCR techniques to amplify circulating fungal DNA, may facilitate…

Voriconazolemedicine.medical_specialtyPathologymedicine.diagnostic_testbusiness.industryRespiratory diseaseHematologyGeneral MedicineNeutropeniamedicine.diseaseAspergillosisGastroenterologyBronchoalveolar lavageAmphotericin B deoxycholateInternal medicinemedicinebusinessFebrile neutropeniaMycosismedicine.drugAnnals of Hematology
researchProduct

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of …

2006

Morbidity and mortality in patients with malignancies are increased by viral infections. These mostly are reactivations of asymptomatic latent infections. They primarily concern clinical entities associated with the reactivation of herpes viruses, such as varicella zoster virus (VZV) and cytomegalovirus (CMV). Respiratory tract infections caused by influenza, parainfluenza or respiratory syncytial virus (RSV) are less common. Since reactivation of latent infections has major clinical impact, antiviral prophylaxis is an attractive approach for patients expecting immunosuppression. The main risk factor for clinically relevant reactivation is profound disruption of cellular immune response. Du…

virusesmedicine.medical_treatmentCongenital cytomegalovirus infectionAntineoplastic AgentsNeutropeniamedicine.disease_causeAntiviral AgentsVirusHerpesviridae03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansRespiratory tract infectionsbusiness.industryVaricella zoster virusvirus diseasesImmunosuppressionHematologymedicine.disease3. Good healthOncologyVirus Diseases030220 oncology & carcinogenesisImmunologyAlemtuzumabbusinessImmunosuppressive Agents030215 immunologymedicine.drugStem Cell TransplantationAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospit…

2012

Invasive fungal disease (IFD) causes increasing morbidity and mortality in haematological cancer patients. Reliable cost data for treating IFD in German hospitals is not available. Objective of the study was to determine the institutional cost of treating the IFD. Data were obtained by retrospective chart review in German hospitals. Patients had either newly diagnosed or relapsed acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS). Direct medical cost was calculated from hospital provider's perspective. A total of 108 patients were enrolled at 5 tertiary care hospitals, 36 IFD patients and 72 controls. The vast majority of IFD patients (74%) were diagnosed with invasive aspergil…

medicine.medical_specialtyMyeloidbusiness.industryMyelodysplastic syndromesRetrospective cohort studyDermatologyGeneral MedicineAspergillosismedicine.diseaseIndirect costsInfectious DiseasesInvasive fungal diseasePharmacotherapymedicine.anatomical_structureInternal medicinemedicineYoung adultbusinessIntensive care medicineMycoses
researchProduct